Isoniazid preventive treatment: predictors of adverse events and treatment completion.
Int J Tuberc Lung Dis
; 17(7): 903-8, 2013 Jul.
Article
em En
| MEDLINE
| ID: mdl-23651743
ABSTRACT
SETTING:
Villa Marelli Institute (VMI), Niguarda Ca'Granda Hospital, Milan, Italy.BACKGROUND:
A recent report on the fatal side effects of isoniazid preventive therapy (IPT) from the United States has re-ignited discussion on the safety of this intervention.OBJECTIVE:
To evaluate IPT feasibility, treatment completion and adverse events (AE) and their determinants under field conditions.METHODS:
Data from consecutive subjects undergoing IPT at the VMI were recorded in an electronic database from 1992 to 2009. Logistic regression analysis was performed to detect completion and AE determinants.RESULTS:
A total of 11,963 patients were included in the study. AE (odds ratio [OR] 2.70, 95%CI 2.22-3.28) and human immunodeficiency virus positive status (OR 5.20, 95%CI 2.10-12.93) were the main determinants of treatment interruption among Italians, while social weakness (no housing/job; OR 2.88, 95%CI 2.43-3.42), AEs (OR 1.33, 95%CI 1.15-1.53, 2.22-3.28) and screening in undocumented subjects (OR 1.20, 95%CI 1.01-1.44) prevailed among foreigners. Age was the main determinant of transaminase increase (OR 1.03, 95%CI 1.03-1.04), as were AEs of the gastrointestinal (OR 1.02, 95%CI 1.02-1.03), central nervous (OR 1.02, 95%CI 1.02-1.05) and peripheral nervous systems (OR 1.04, 95%CI 1.02-1.05).CONCLUSION:
This analysis demonstrates the feasibility and safety of IPT, with determinants of interruption and AEs being predictable and addressable.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tuberculose
/
Tuberculose Latente
/
Isoniazida
/
Antituberculosos
Idioma:
En
Ano de publicação:
2013
Tipo de documento:
Article